Insights

Clinical Translation Regenerative medicine focus suggests REMED can act as a translational partner to biotech firms and hospitals, offering preclinical development, regulatory strategy, and early-phase clinical translation services to accelerate bench-to-clinic efforts.

Digital Transformation Current tech stack indicates a basic online presence and analytics use; opportunities exist to offer digital infrastructure upgrades such as a modern LIMS/ELN for experimental data management, secure cloud hosting, regulatory-compliant data workflows, and CRM/marketing automation to attract collaborations.

Funding Readiness With revenue in the low range, REMED may pursue grants, collaborations, or contracts; sales opportunities include grant management tools, proposal development support, and partnership financing options that help scale regenerative medicine programs.

Strategic Partnerships The company's specialization in regenerative medicine and a relatively small, specialized team create a natural opening for strategic collaborations with international research centers, CROs, and pharma partners seeking niche regenerative expertise.

Skills Training A mid-sized, highly skilled team signals demand for training, workshops, and technical services; potential offerings include capacity-building programs, regulatory-compliance training, and turnkey workflow education to accelerate project delivery.

Similar companies to REMED

REMED Tech Stack

REMED uses 8 technology products and services including gstatic.com, LinkedIn, PHP, and more. Explore REMED's tech stack below.

gstatic.com
Content Delivery Network
LinkedIn
Online Community Software
PHP
Programming Languages
WhatsApp
Social Sharing
Animate.css
UI Frameworks
Google Search Console
Web Analytics
jQuery Waypoints
Web Tools And Plugins
Facebook
Widgets

Media & News

REMED's Email Address Formats

REMED uses at least 2 format(s):

REMED Email Formats	Example	Percentage
FLast@remed.com	JDoe@remed.com	91%
First.Last@remed.com	John.Doe@remed.com	8%
LastF@remed.com	DoeJ@remed.com	1%
First.Last@tums.ac.ir	John.Doe@tums.ac.ir	94%
FirstLast@tums.ac.ir	JohnDoe@tums.ac.ir	5%
FLast@tums.ac.ir	JDoe@tums.ac.ir	1%

Frequently Asked Questions

What is REMED's stock symbol?

REMED is a publicly traded company; the company's stock symbol is REMEDY.HE.

What is REMED's official website and social media links?

REMED's official website is tums.ac.ir and has social profiles on LinkedIn.

What is REMED's NAICS code?

REMED's NAICS code is 5417 - Scientific Research and Development Services.

How many employees does REMED have currently?

As of July 2026, REMED has approximately 55 employees across 5 continents, including North AmericaAsiaEurope. Key team members include Chief Executive Officer: C. R.Chief Information Officer: M. H.Vice President Of Operations: E. S.. Explore REMED's employee directory with LeadIQ.

What industry does REMED belong to?

REMED operates in the Research Services industry.

What technology does REMED use?

REMED's tech stack includes gstatic.comLinkedInPHPWhatsAppAnimate.cssGoogle Search ConsolejQuery WaypointsFacebook.

What is REMED's email format?

REMED's email format typically follows the pattern of FLast@remed.com. Find more REMED email formats with LeadIQ.

When was REMED founded?

REMED was founded in 2020.

REMED

Q: What is REMED's official website and social media links?

REMED's official website is tums.ac.ir. REMED has social profiles on LinkedIn.

Q: How many employees does REMED have currently?

REMED has approximately 55 employees.

Q: What technology does REMED use?

REMED's tech stack includes Google Tag Manager, Google Maps, X-UA-Compatible, LinkedIn, Nginx.

Q: What is REMED's NAICS code?

REMED's NAICS code is 5417 (Scientific Research and Development Services).

Research ServicesTehrān, Iran51-200 Employees

REMED is a Tehran-based research services company focused on regenerative medicine, an area aiming to restore normal function to cells, tissues, or organs harmed by disease or injury. Its work centers on turning promising laboratory findings into clinical applications, reflecting a growing emphasis on translating research from the lab to patient care. The organization operates with a mid-sized team that supports its translational science activities. Its customers include researchers, healthcare institutions, and clinicians seeking regenerative treatment options. By bridging fundamental research and patient-ready therapies, REMED addresses the practical challenge of moving scientific discoveries into usable medical interventions. Located in Tehran, Iran, the company sits within the broader regenerative medicine landscape that prioritizes clinical translation.